India, Aug. 28 -- Immuron Limited (IMRN,IMC.AX), a commercial and clinical-stage biopharmaceutical company focused on developing and commercializing orally delivered polyclonal antibody products, reported preliminary results for the financial year ended June 30, 2026.
The company highlighted record sales growth, a narrower net loss, a stronger cash position and continued progress across its clinical and commercial programs.
FY26 Financial HighlightsImmuron reported FY26 revenue from contracts with customers of A$7.71 million, up 5.9% from A$7.29 million in FY25.
Gross profit increased to A$4.98 million from A$4.77 million in the prior year.
The company's net loss narrowed to A$3.84 million, or A$0.0129 per share, from a loss of A$5.22 m...